Loading...
•
Jun 30, 2021
Exact Sciences Q2 2021 Earnings Report
Generated record results for Cologuard and Oncotype DX.
Key Takeaways
Exact Sciences Corp. announced revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020. The company reported a net loss of $176.9 million, or $1.03 per share, compared to a net loss of $68.1 million, or $0.45 per share for the same period of 2020.
Total revenue was $434.8 million, an increase of 62 percent.
Screening revenue was $263.9 million, an increase of 101 percent.
Precision Oncology revenue was $137.8 million, an increase of 34 percent.
COVID-19 testing revenue was $33.1 million, a decrease of 4 percent.
Revenue by Segment
Forward Guidance
The company anticipates revenue of $1,705-$1,745 million during 2021, including Screening revenue of $1,100-$1,125 million, Precision Oncology revenue of $530-$540 million, and COVID-19 testing revenue of $75-$80 million.
Challenges Ahead
- Lower Screening revenue expectations are primarily due to the one-time downward revenue adjustment of $12.1 million referenced above and COVID-19 dynamics negatively impacting the business, including reduced physician office access for our field sales teams and fewer patient wellness visits.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...